Curcumin in Sepsis: Anti-Inflammatory Mechanisms, Nano-Formulations, and Evidence from Preclinical and Early Clinical Studies
Journal of Society Medicine · 31.05.2026 · 5 (5) · 149-156
DOI: 10.71197/jsocmed.v5i5.280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Society Medicine, online erschienen am 31.05.2026. Verfasst von Yeni Puspawani und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Introduction
Sepsis is driven by dysregulated host inflammation, cytokine amplification, endothelial injury, and oxidative stress, with nuclear factor kappa B signaling acting as a central regulatory axis. Curcumin, the principal bioactive compound of turmeric, has gained attention as a potential adjunctive therapy because of its pleiotropic anti-inflammatory, antioxidant, and immunomodulatory properties; however, its translational relevance in sepsis remains unclear.
Methods
This narrative review synthesizes evidence from preclinical sepsis models, mechanistic studies, systematic reviews, meta-analyses, and early randomized or controlled clinical trials that evaluated curcumin, nano-curcumin, or curcumin-based formulations for sepsis and critical illness.
Results
Preclinical evidence indicates that curcumin attenuates macrophage hyperactivation, suppresses TNF-α, IL-6, and IL-1β signaling, and modulates pyroptosis-related inflammatory pathways. In polymicrobial sepsis models, curcumin inhibited the HMGB1/TLR4/NF-κB pathway, reduced HMGB1 release, and limited NF-κB p65 nuclear translocation in polymicrobial sepsis models. Higher doses demonstrated stronger protection against multi-organ injury, partly through ferroptosis suppression via ACSL4/glutathione peroxidase 4 (GPX4) regulation and inhibition of protein lactylation via p300 downregulation. Early ICU trials suggest that enterally administered nano-curcumin may reduce inflammatory and endothelial biomarkers while enhancing antioxidant responses via Nrf2 signaling. Clinical signals include improved SOFA scores and reduced mechanical ventilation duration, although mortality and ICU length-of-stay remain inconsistent. Pooled evidence from critically ill populations also indicates modest improvements in organ dysfunction and selected hepatic and nutritional biomarkers.
Conclusion
Curcumin demonstrates strong biological and translational plausibility in sepsis through multi-target modulation of inflammatory, oxidative, and cell death pathways. However, current clinical evidence remains limited and heterogeneous, underscoring the need for larger, well-designed trials with standardized formulations and clinically meaningful endpoints.
Zitieren
APA
Puspawani, Y., Rusip, G., & Napiah, A. (2026). Curcumin in Sepsis: Anti-Inflammatory Mechanisms, Nano-Formulations, and Evidence from Preclinical and Early Clinical Studies. Journal of Society Medicine, 5(5), 149-156. https://doi.org/10.71197/jsocmed.v5i5.280
Vancouver
Puspawani Y, Rusip G, Napiah A. Curcumin in Sepsis: Anti-Inflammatory Mechanisms, Nano-Formulations, and Evidence from Preclinical and Early Clinical Studies. Journal of Society Medicine. 2026;5(5):149-156. doi:10.71197/jsocmed.v5i5.280
BibTeX
@article{Puspawani2026,
author = {Puspawani, Yeni and Rusip, Gusbakti and Napiah, Ali},
title = {Curcumin in Sepsis: Anti-Inflammatory Mechanisms, Nano-Formulations, and Evidence from Preclinical and Early Clinical Studies},
journal = {Journal of Society Medicine},
year = {2026},
volume = {5},
number = {5},
pages = {149--156},
doi = {10.71197/jsocmed.v5i5.280}
}
EUVIMED